TheInfoListRev V5.1.39

Topic summary

Zaleplon

Zaleplon
Clinical dataTrade namesSonata, othersAHFS/Drugs.comMonographMedlinePlusa601251License data
Addiction
liabilityModerateRoutes of
administrationBy mouthDrug classNonbenzodiazepineATC code
Legal statusLegal status
Pharmacokinetic dataBioavailability30% (oral)MetabolismLiver aldehyde oxidase (91%), CYP3A4 (9%)MetabolitesNo active metabolitesOnset of action10–30 minutesElimination half-life1 hourDuration of action4–6 hoursExcretionKidneyIdentifiers
  • N-(3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl)phenyl)-N-ethylacetamide
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.126.674Chemical and physical dataFormulaC17H15N5OMolar mass305.341 g·mol3D model (JSmol)
  • CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
  • InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
  • Key:HUNXMJYCHXQEGX-UHFFFAOYSA-N
(verify)

Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.

Wikipedia source